Cargando…

Developing treatments for pulmonary arterial hypertension

Developing new treatments for pulmonary arterial hypertension (PAH) is a challenge. We have enjoyed success with regulatory approvals for three drug classes—prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. But we have also seen some disappointing results, for exa...

Descripción completa

Detalles Bibliográficos
Autor principal: Wilkins, Martin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641724/
https://www.ncbi.nlm.nih.gov/pubmed/23662193
http://dx.doi.org/10.4103/2045-8932.109961
_version_ 1782268050090754048
author Wilkins, Martin R.
author_facet Wilkins, Martin R.
author_sort Wilkins, Martin R.
collection PubMed
description Developing new treatments for pulmonary arterial hypertension (PAH) is a challenge. We have enjoyed success with regulatory approvals for three drug classes—prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. But we have also seen some disappointing results, for example, from studies with vasoactive intestinal polypeptide, statins and tergolide. Animal models are an unreliable predictor of efficacy in humans. The best model for the disease is the patient. This review discusses three major issues facing the evaluation of drugs in PAH patients—target validation, choosing the right dose, and early trial design.
format Online
Article
Text
id pubmed-3641724
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-36417242013-05-09 Developing treatments for pulmonary arterial hypertension Wilkins, Martin R. Pulm Circ Thomas L. Petty Aspen Lung Conference 55th Annual Meeting: Roger S. Mitchell Lecture Developing new treatments for pulmonary arterial hypertension (PAH) is a challenge. We have enjoyed success with regulatory approvals for three drug classes—prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. But we have also seen some disappointing results, for example, from studies with vasoactive intestinal polypeptide, statins and tergolide. Animal models are an unreliable predictor of efficacy in humans. The best model for the disease is the patient. This review discusses three major issues facing the evaluation of drugs in PAH patients—target validation, choosing the right dose, and early trial design. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3641724/ /pubmed/23662193 http://dx.doi.org/10.4103/2045-8932.109961 Text en Copyright: © Pulmonary Circulation http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Thomas L. Petty Aspen Lung Conference 55th Annual Meeting: Roger S. Mitchell Lecture
Wilkins, Martin R.
Developing treatments for pulmonary arterial hypertension
title Developing treatments for pulmonary arterial hypertension
title_full Developing treatments for pulmonary arterial hypertension
title_fullStr Developing treatments for pulmonary arterial hypertension
title_full_unstemmed Developing treatments for pulmonary arterial hypertension
title_short Developing treatments for pulmonary arterial hypertension
title_sort developing treatments for pulmonary arterial hypertension
topic Thomas L. Petty Aspen Lung Conference 55th Annual Meeting: Roger S. Mitchell Lecture
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641724/
https://www.ncbi.nlm.nih.gov/pubmed/23662193
http://dx.doi.org/10.4103/2045-8932.109961
work_keys_str_mv AT wilkinsmartinr developingtreatmentsforpulmonaryarterialhypertension